| Title: |
TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma. |
| Authors: |
Breinholt, Marie Fredslund1,2 (AUTHOR) mariebreinholt@hotmail.com, Schejbel, Lone1 (AUTHOR), Gang, Anne Ortved2,3 (AUTHOR), Christensen, Ib Jarle1 (AUTHOR), Nielsen, Torsten Holm3,4,5 (AUTHOR), Pedersen, Lars Møller2,5 (AUTHOR), Høgdall, Estrid1,2 (AUTHOR), Nørgaard, Peter1,6 (AUTHOR) |
| Source: |
European Journal of Haematology. Dec2024, p1. 7p. 2 Illustrations. |
| Subject Terms: |
*GENETIC mutation, *OVERALL survival, *MYELOID differentiation factor 88, *LYMPHOMAS, *BIOMARKERS |
| Abstract: |
ABSTRACT Introduction Methods Results Conclusion Large B‐cell lymphoma (LBCL) taxonomy has moved in the direction of a molecular classification, but further clinical experience is needed. We present high‐risk gene mutations, which predict outcome in an exploratory study of a consecutive real‐world cohort of patients with primary LBCL treated with R‐CHOP or R‐CHOP‐like therapy.The study was a Registry Study Research Project. Sixty‐one patients with LBCL, who had a diagnostic tumor sample successfully examined with a 59‐gene next‐generation sequencing (NGS) panel as a part of routine clinical work, were included in an otherwise unselected cohort. Data were extracted from patient files and pathology reports.Mutations in NOTCH2 (HR 9.69; 95% CI [2.46–38.11]; p = 0.0012), PRDM1 (HR 3.54; 95% CI [1.03–12.22]; p = 0.045), and TP53 (HR 5.89; 95% CI [1.71–20.32]; p = 0.005) were significantly associated with inferior survival in patients with primary LBCL treated with intention to cure with at least three series of R‐CHOP or R‐CHOP‐like therapy. Neither MYD88 (HR 0.66; 95% CI (0.17–2.49), p = 0.54) nor CD79B (HR 0.84;95% CI (0.18–3.88), p = 0.82) mutations were associated with inferior survival.With a targeted gene panel and NGS methodology feasible in daily diagnostic routine, we identified high‐risk gene mutations with a significant prognostic impact of which TP53 mutations were reproducible across validation cohorts. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
